Neurimmune

Neurimmune is a biopharmaceutical company that translates human immune memory into revolutionary treatments. The company primarily develops novel immunotherapies based on Artificial Immune Memory (AIM) technology, focusing on restoring the natural immune capacity of T cells and creating new drugs capable of curing cancer. Neurimmune generates recombinant human monoclonal antibodies with biophysical properties closely resembling those found in healthy elderly individuals. These antibodies exhibit unique characteristics such as target selectivity, superior pharmacodynamics, and low immunogenicity, resulting in an excellent risk profile and high efficacy. Neurimmune’s pipeline includes programs targeting various disease-associated targets and specific target conformations. These encompass misfolded, oligomeric, fibrillar, or post-translationally modified forms of disease-related proteins, as well as physiological conformations involved in major disease pathways.